Excellergy has emerged from stealth mode with USD 70 million Series A financing led by Samsara BioCapital to advance its effector cell response inhibitor (ECRI) platform targeting IgE-mediated allergic pathways. The company's triple-mechanism approach rapidly clears IgE from mast cell and basophil FcεRI receptors without activation, neutralises free IgE and downregulates receptor expression. Excellergy plans clinical entry for its lead program in early 2026, addressing limitations of existing IgE-targeted therapies through upstream intervention in the allergic cascade.

The novel mechanism enables faster onset and more comprehensive control across allergic conditions including asthma, atopic dermatitis and food allergies compared to monoclonal antibodies. Excellergy's platform originated from Red Tree Venture Capital incubation in 2021, leveraging breakthroughs in IgE-receptor binding interactions. CEO leadership emphasized the potential to redefine treatment standards rather than incremental improvement, targeting a substantial market opportunity across multiple allergic diseases affecting millions globally through a disease-modifying approach.

PharmCube's NextBiopharm® database shows that Excellergy joins 24 active developers of IgE-targeting allergy drugs globally. Click here to request a free trial for NextBiopharm®.